Introduction
Fenclofenac has a half-life in man of between 12 and 24 hours (depending on dosage) and measurements of plasma fenclofenac levels have indicated that twice daily dosage is sufficient for clinical maintenance.
This work formed part of a multicentre, openended, study to determine the optimal dosage range and long-term tolerance of fenclofenac in a variety of rheumatic disorders.
Material and Methods
Thirty-four patients were admitted to the study; 5 males and 13 females with rheumatoid arthritis (RA); 11 females with osteoarthrosis (OA); one male and one female with psoriatic arthritis (PsA); and 3 females with non-articular rheumatism (NAR). The mean age at the start of the study was 55 years (range 40 to 76 years). The mean duration of treatment (to compilation of data) was 45 weeks (range I to 104 weeks). Table 1 shows the duration of treatment in the different disorders. It can be seen that the periods of treatment in PsA and NAR were short, with a wide range in those with RA and OA. Review was at weekly intervals until stable dosage was achieved. This permitted an increase of dose at fortnightly intervals when the laboratory measurements, including serum fenclofenac levels, at one week's treatment were available. Patients were started at a dose of 300 mg twice daily and dosage was increased initially by 200 mg increments, but later in the study by 300 mg increments. When an effective dose level was achieved, this was maintained indefinitely.
Results Table 2 shows the highest daily doses of fenclofenac administered to all patients; only a few patients received the maximal permitted dosage. In Table 3 the dosages required to maintain control of symptoms are tabulated: while some patients with RA were controlled on a low dose, others required higher dosages; however, OA was usually controlled by 1.2 g per day or less.
Ten patients withdrew because of inadequate pain relief; 5 with RA, 3 with OA and 2 with PsA. The doses at time of withdrawal are shown in Table 4 . None of these patients was receiving over 1.2 g per day and 2 withdrew after only one week at 600 mg per day.
Minor possible side-effects were reported by 20 patients. Ten patients had disturbance of the gastrointestinal tract (nausea and abdominal pain each being experienced by 4 patients; vomiting, diarrhoea and constipation each by 2 patients and indigestion, heartburn and loose stool each by one patient), 14 of the central nervous system (headache being reported by 8 patients, dizziness by 5, light or muzzy head by 4, faintness or drowsiness each by 2 patients, and one patient each with noise in the ears, depression, tiredness, hot headedness, or thudding in the head), 7 of the skin (4 having minor rash, 2 sore skin, and one mouth ulcers), 3 of the eyes (sore in 2 patients, and one each with 'grit in eyes', 'eyes feel funny'), and one of the cardiovascular system (swollen ankles). However, the generally mild character of reported side-effects is substantiated by the fact that withdrawal of therapy was effected in only 2 cases. Both were females and suffered from OA. One developed a skin rash on a dose of 900 mg per day, after 20 weeks of therapy. The other was noted to have lens cataracts after 600 mg per day for 27 weeks, but further investigation indicated that these were not drug-related. The ophthalmological opinion was that these were familial in origin, her younger brother having been seen at that time complaining of failing vision. He exhibited similar cataracts but had never received fenclofenac. Transient minor elevation of alkaline phosphatase or transaminases was noted in 2 and 8 patients respectively, and minor rises of blood urea were noted in 3 patients. However, abnormal laboratory parameters necessitated the withdrawal of only 2 patients. One female with NAR was noted to have rising transaminases on a dose of 800 mg per day after twelve weeks' therapy.
Levels returned to normal on cessation of therapy. On questioning, a past history of possible cholecystitis was obtained. The other patient was a female with RA. A rising urea was noted on 1.5 g fenclofenac per day after 96 weeks of treatment.
Conclusions
It is concluded that the required dose of fenclofenac is variable and should be related to the clinical response up to 1.8 g per day. Patients with osteoarthrosis usually require around 900 mg per day, while those with rheumatoid arthritis may require higher doses, though some are controlled on only 600 mg per day. At these dose levels fenclofenac is well tolerated.
Summary
Fenclofenac was administered to 34 patients with a variety of rheumatic complaints. Patients with osteoarthrosis required around 900 mg per day to control symptoms. Those with rheumatoid arthritis often needed higher doses, though some were controlled on only 600 mg per day. Two patients were withdrawn because of abnormal laboratory parameters, one because of skinlrash and one was noted to have lens cataracts (Later shown not to be drug related). At these dose levels fenclofenac appears to be well tolerated.
